Valentino Garavani Dies at 93, Leaving Behind the Timeless Legacy of Valentino Red 
Memory Chip Shortage Drives Higher Gadget Prices and Weakens Global Tech Demand 
Lynas Rare Earths Shares Surge as Quarterly Revenue Jumps on Strong Prices 
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors 
Elon Musk Says Tesla Cybercab and Optimus Production Will Start Slowly Before Rapid Growth 
Brazil Supreme Court Orders Asset Freeze of Nelson Tanure Amid Banco Master Investigation 
Court Allows Expert Testimony Linking Johnson & Johnson Talc Products to Ovarian Cancer 
Trump Signs Executive Order to Limit Wall Street Investment in Single-Family Homes 
United Airlines Posts Record Q4 Revenue as Premium Demand Lifts Earnings 
Renault Group Global Sales Rise 3.2% in 2025 on Strong International and EV Demand 
Baidu Shares Surge After Official Launch of Advanced Ernie 5.0 AI Model 
Walmart to Cut PhonePe Stake in IPO as Tiger Global and Microsoft Exit 
Morgan Stanley Flags High Volatility Ahead for Tesla Stock on Robotaxi and AI Updates 
FSU Criticizes ANZ Over Suncorp Bank Job Cuts Amid Post-Acquisition Commitments 
Valero Makes First Venezuelan Crude Purchase Under New U.S.-Caracas Deal 
Rio Tinto Posts Strong Q4 Iron Ore and Copper Output on Operational Recovery 
CARMIEL, Israel, May 01, 2017 -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®, today announced that it will report first quarter 2017 financial results and provide a corporate update on Wednesday, May 10, 2017 at 8:30 am ET.
To participate in the conference call, please dial the following numbers prior to the start of the call: United States: +1-844-358-6760; International: +1-478-219-0004. The conference call will also be broadcast live and available for replay for two weeks on the Company’s website, www.protalix.com, in the Events Calendar of the Investors section. Please access the Company’s website at least 15 minutes ahead of the conference to register, download, and install any necessary audio software.
About Protalix BioTherapeutics, Inc.
Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®. Protalix’s unique expression system presents a proprietary method for developing recombinant proteins in a cost-effective, industrial-scale manner. Protalix’s first product manufactured by ProCellEx, taliglucerase alfa, was approved for marketing by the U.S. Food and Drug Administration (FDA) in May 2012 and, subsequently, by the regulatory authorities of other countries. Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights for taliglucerase alfa, excluding Brazil, where Protalix retains full rights. Protalix’s development pipeline includes the following product candidates: pegunigalsidase alfa, a modified version of the recombinant human alpha-GAL-A protein for the treatment of Fabry disease; OPRX-106, an orally-delivered anti-inflammatory treatment; alidornase alfa for the treatment of Cystic Fibrosis; and others.
Investor Contact Marcy Nanus The Trout Group, LLC 646-378-2927 [email protected]
